16-30 of 131
Aldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
CME/CEAldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
Jamie P. Dwyer, MD
J. Matthew Luther, MD, MSCI
Vivek Bhalla, MD
Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
CME/CEContinuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
Christian Mende, MD, FACP, FACN, FASN, FASH, FAHA
Deepak Bhatt, MD, MPH, MBA, FACC, FAHA
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
Claudia Seikrit, MD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
NephrologyOptimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CEVous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
- advertisement
Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
CME/CEShifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Stephen J. Greene, MD
Anne Louise Peters, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®Emerging Therapies in IgAN: Who Could Benefit the Most?
Richard Lafayette, MD, FACP
Hong Zhang
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®Emerging Evidence: IgAN Disease-Modifying Agents
Richard Lafayette, MD, FACP
Hong Zhang
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Hong Zhang
Dana Rizk, MD
Hong Zhang
- advertisement
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®Mechanism-Based Targeting: Why APRIL Matters in IgAN
Suzuki Yusuke, MD, PhD
Dana Rizk, MD
Dana Rizk, MD
Suzuki Yusuke, MD, PhD
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Richard Lafayette, MD, FACP
Suzuki Yusuke, MD, PhD
